Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Reproduction Ardana's way

Despite the importance of reproductive medicine to people's lives, it has been a singularly unrewarding area for new companies. The marketplace is dominated by a few big players: Johnson & Johnson (JNJ), Abbott Laboratories (ABT), Wyeth (WYE) and Serono S.A. (SWX:SEO; SRA). Ardana Ltd. thinks there is room for one more. The company is following a low-risk strategy of in-licensing and reformulating existing compounds for development in the European market, as well as repositioning off-patent niche products for reproductive indications.

Read the full 807 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers